Shopping Cart
Remove All
Your shopping cart is currently empty
M435-1279 is a UBE2T inhibitor that blocks UBE2T-mediated degradation of RACK1, thereby inhibiting the hyperactivation of the Wnt/β-catenin signaling pathway.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $31 | 6-8 weeks | 6-8 weeks | |
| 5 mg | $73 | 6-8 weeks | 6-8 weeks | |
| 10 mg | $116 | 6-8 weeks | 6-8 weeks | |
| 25 mg | $223 | 6-8 weeks | 6-8 weeks | |
| 50 mg | $333 | 6-8 weeks | 6-8 weeks | |
| 100 mg | $470 | 6-8 weeks | 6-8 weeks | |
| 200 mg | $662 | 6-8 weeks | 6-8 weeks | |
| 1 mL x 10 mM (in DMSO) | $87 | - | In Stock |
| Description | M435-1279 is a UBE2T inhibitor that blocks UBE2T-mediated degradation of RACK1, thereby inhibiting the hyperactivation of the Wnt/β-catenin signaling pathway. |
| In vitro | M435-1279 (0, 2, 4, 8, 16, 31 μM; 48 h) significantly inhibits the growth of AGS, HGC27, and MKN45 cells. It also inhibits cell viability with IC50s of 16.8, 11.88, 7.76, and 6.93 μM for GES-1, HGC27, AGS, and MKN45 cells, respectively. M435-1279 (31 nM to 500 μM) binds to UBE2T protein with a KD value of 50.5 μM and (11.88 μM; 48 h) blocks the ubiquitination of RACK1, thereby inhibiting the hyperactivation of the Wnt/β-catenin pathway[1]. |
| In vivo | M435-1279 (5 mg/kg/day; intratumor injection; 18 days) inhibits tumor growth and induces increased expression of RACK1 proteins while decreasing expression of Ki-67 and β-catenin proteins in intratumor tumors[1]. |
| Molecular Weight | 419.47 |
| Formula | C18H17N3O5S2 |
| Cas No. | 1359431-16-5 |
| Smiles | NS(=O)(=O)c1ccc(NC(=O)c2c(O)c3c4CCCCc4sc3[nH]c2=O)cc1 |
| Relative Density. | 1.620 g/cm3 (Predicted) |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | Chloroform: < 1 mg/mL (insoluble or slightly soluble) DMSO: 45 mg/mL (107.28 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+90% Saline: 2 mg/mL (4.77 mM), Sonication is recommeded. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.